We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Nonetheless, an exploratory CANTOS genomic substudy revealed a 62% major adverse cardiovascular event (MACE) reduction with canakinumab (HR, 0.38; 95% CI, 0.15-0.96) in patients with TET2 clonal hematopoiesis of indeterminate potential (CHIP).”
Evaluates immune response to canakinumab in clonal hematopoiesis, suggesting potential treatments.
ClinicalTrials.gov Identifier: NCT01327846.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Svensson et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: